Advanced Therapeutics最新文献_第6页

Advancements in Selenium-Based Nanomedicine: Transforming Cancer Therapy Across Diverse Types 硒基纳米医学的进展：改变不同类型的癌症治疗

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-24 DOI: 10.1002/adtp.202500042

Prashant Kesharwani, Kratika Halwai, Garima Gupta, Saurav Kumar Jha, Khang Wen Goh, Mohammed A.S. Abourehab

{"title":"Advancements in Selenium-Based Nanomedicine: Transforming Cancer Therapy Across Diverse Types","authors":"Prashant Kesharwani, Kratika Halwai, Garima Gupta, Saurav Kumar Jha, Khang Wen Goh, Mohammed A.S. Abourehab","doi":"10.1002/adtp.202500042","DOIUrl":"10.1002/adtp.202500042","url":null,"abstract":"Selenium (Sel) is an important trace element that plays a role in a variety of biological processes and reactions across species. It is well known for its antiviral, antioxidant, cytokine-modulating, immune-boosting, and anticoagulant characteristics, which have the potential to help manage illnesses like cancer. With the evolution of nanotechnology, customized medicine has made great progress, notably in increasing medication targeting while reducing the toxicity of anticancer treatments. Targeted nano-drug delivery systems are now being used to circumvent multidrug resistance and minimize side effects. By encapsulating medicines, these systems improve their solubility and tumor-targeting efficacy via active and passive transport modes. Sel nanoparticles (NPs) (Sel-NPs) have been identified as a potential anticancer platform because to their regulated size, excellent drug-loading capacity, increased antitumor efficacy, and reduced cytotoxicity. Importantly, no significant health hazards or toxicities have been documented in people or animals after utilizing these biogenic synthetic materials, making them a cost-effective and environmentally friendly solution. This review focuses on current breakthroughs in cancer therapy and preventive research using synthetic and biogenic Sel-NPs alone and in combination with chemo-, radiation-, and immunotherapy, as well as the hurdles faced during their development.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polydopamine-Integrated Nanomedicine through Dual Metabolic Intervention with Enhanced Photothermal Therapy against Triple-Negative Breast Cancer 多多巴胺整合纳米药物通过双代谢干预和增强光热疗法治疗三阴性乳腺癌

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-22 DOI: 10.1002/adtp.202400570

Chenlu Xu, Yujuan Gao, Xiaoyu Zhang, Fan Jia, Zian Pan, Mingjun Li, Weifeng Wang, Xianlei Li, Yan Wu

{"title":"Polydopamine-Integrated Nanomedicine through Dual Metabolic Intervention with Enhanced Photothermal Therapy against Triple-Negative Breast Cancer","authors":"Chenlu Xu, Yujuan Gao, Xiaoyu Zhang, Fan Jia, Zian Pan, Mingjun Li, Weifeng Wang, Xianlei Li, Yan Wu","doi":"10.1002/adtp.202400570","DOIUrl":"10.1002/adtp.202400570","url":null,"abstract":"Combining metabolic therapy with photothermal therapy (PTT) shows promise for the treatment of triple-negative breast cancer (TNBC). However, a strategy is still required to effectively overcome the metabolic adaptation of TNBC with thermotolerance during thermotherapy, thereby enhancing therapeutic outcomes. In this study, the polydopamine-integrated nanomedicine is designed, with glucose oxidase (GOx) chemically conjugated to its surface and curcumin (Cur)-loaded calcium phosphate (CaP) shell. The outer CaP layer disintegrates in response to the acidic environment of tumor cells, releasing calcium ions with the calcium efflux inhibitor Cur, which causes mitochondrial functional disruption by inducing mitochondrial calcium overload. Concurrently, GOx consumes intracellular glucose to inhibit glycolysis. The dual intervention of mitochondrial metabolism and glycolysis serves to counteract the metabolic adaptations in TNBC, effectively blocking the pathways of energy supply, which results in a 56.61% reduction of ATP. In addition, inhibition of ATP production by dual metabolic regulation can downregulate the expression of heat shock proteins (HSPs) and sensitized PTT, the HSP70 level and HSP90 level are downregulated by 25.68% and 41.89%, respectively. This study provides new insights into combining metabolic therapy and PTT for the treatment of TNBC.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cold Plasma Generates a Localized Inflammatory Response and Promotes Muscle Repair 冷等离子体产生局部炎症反应并促进肌肉修复

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-20 DOI: 10.1002/adtp.202500097

Carly J. Smith, Amanda R. Watkins, Abigail A. Lucas, Arianna J. Moniodes, Conn Ritchie, Thomas P. Thompson, Thomas P. Schaer, Brendan F. Gilmore, Noreen J. Hickok, Theresa A. Freeman

{"title":"Cold Plasma Generates a Localized Inflammatory Response and Promotes Muscle Repair","authors":"Carly J. Smith, Amanda R. Watkins, Abigail A. Lucas, Arianna J. Moniodes, Conn Ritchie, Thomas P. Thompson, Thomas P. Schaer, Brendan F. Gilmore, Noreen J. Hickok, Theresa A. Freeman","doi":"10.1002/adtp.202500097","DOIUrl":"10.1002/adtp.202500097","url":null,"abstract":"The FDA-approved Renuvion cold plasma device is currently used for dermal skin tightening procedures and subdermal tightening after liposuction. Anecdotally, patients report improved tissue healing outcomes following treatment. The most likely explanation for this is plasma-generated reactive species which are inflammatory but also activate cellular signaling pathways, stimulate antioxidant responses, and activate immune cells. In this study, we aimed to determine the immediate and long-term molecular effects of a single plasma treatment on surgically injured muscle and the soft tissue envelope. We used RNA sequencing, histology, and immunohistochemistry to determine changes to the tissue following treatment. Neutrophils and mast cells rapidly mobilize 6 h after treatment in conjunction with an upregulated cellular antioxidant response. Additionally, genes identified by RNAseq indicate upregulated pro-regenerative muscle-tissue-protective gene transcripts and downregulated apoptotic pathway transcripts in the muscle tissue 6 h after treatment. The histology and RNAseq results from 4- and 14-days post plasma treatment indicate that these early inflammatory and antioxidant events drive muscle regeneration to skew toward myogenic differentiation over adipogenesis. Thus, we conclude that a single plasma treatment results in an immediate inflammatory and antioxidant response that enhances long-term muscle fiber repair through reduced adipogenesis.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202500097","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Narrative Review on Efficacy of Cell- and Tissue-Based Therapies for Diabetic Foot Ulcer 以细胞和组织为基础的治疗糖尿病足溃疡的疗效综述

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-19 DOI: 10.1002/adtp.202400335

Behnaz Niroomand, Ibrahim Mohammadzadeh, Maryam Tabarzad, Elham Mohit

{"title":"A Narrative Review on Efficacy of Cell- and Tissue-Based Therapies for Diabetic Foot Ulcer","authors":"Behnaz Niroomand, Ibrahim Mohammadzadeh, Maryam Tabarzad, Elham Mohit","doi":"10.1002/adtp.202400335","DOIUrl":"10.1002/adtp.202400335","url":null,"abstract":"Diabetic foot ulcers (DFUs) are complex, making conventional treatments challenging in restoring skin tissue. Stem cell therapy (SCT) and skin replacement therapy (SRT) offer promising solutions by addressing prolonged inflammation, impaired cell proliferation, and reduced extracellular support. Here, based on the origin of cells, SCTs are categorized into embryonic, induced pluripotent, fetal, and adult stem cells (ASCs). Mesenchymal stem cells are among the most employed types of ASCs in clinical trials for treating DFUs. Furthermore, their delivery routes, and stem-cell-derived products are also discussed. However, the lack of phase III/V clinical trials limits their clinical use. SRTs are classified by tissue origin (human or animal) and product cellularity. Clinical trials and systematic reviews indicate that placenta-based grafts (e.g., EpiFix), acellular dermal matrices from human cadaver skin (e.g., DermACell and Graftjacket), and bioengineered cell-based products (e.g., Apligraf and Dermagraft) are the most effective and safe for SRT. Both SCT and SRT are evolving fields with ongoing challenges, including injection barriers, cell reprogramming risks, ethical concerns, foreign body reactions, and a lack of long-term follow-up studies.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging Therapeutic Strategies for Hearing Loss 新兴的听力损失治疗策略

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-16 DOI: 10.1002/adtp.202500127

Shanying Han, Tian Shen, Weiwei He, Hao Wei, Xiaolong Zhao, Wen Yang, Chuan Bu, Xinghua Tang, Yu Zhao, Jiangang Fan

{"title":"Emerging Therapeutic Strategies for Hearing Loss","authors":"Shanying Han, Tian Shen, Weiwei He, Hao Wei, Xiaolong Zhao, Wen Yang, Chuan Bu, Xinghua Tang, Yu Zhao, Jiangang Fan","doi":"10.1002/adtp.202500127","DOIUrl":"10.1002/adtp.202500127","url":null,"abstract":"Hearing loss (HL) is a significant global health challenge, affecting billions of people and severely impacting quality of life. While traditional interventions such as hearing aids and cochlear implants mitigate symptoms, they fail to address the underlying causes of HL, especially in cases involving severe damage to hair cells or spiral ganglion neurons. Emerging therapeutic strategies, including biomaterials, nanocarrier drug delivery systems, gene therapy, and extracellular vesicle (EV)-based approaches, have demonstrated significant potential in promoting inner ear regeneration and restoring auditory function. Biomaterials mimic the extracellular matrix to guide inner ear cell regeneration, while nanocarriers and EVs enhance the targeted and sustained delivery of therapeutic agents. Gene therapy offers opportunities to correct genetic mutations, addressing hereditary HL. However, challenges such as the anatomical complexity of the cochlea, the blood-labyrinth barrier, and limited regenerative capacity persist. Future research must focus on scalable, biocompatible, and clinically safe delivery systems to advance the clinical translation of these innovative therapies. This review underscores the potential of integrating these strategies to develop effective and long-lasting treatments for HL.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202500127","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Issue Information (Adv. Therap. 5/2025) 发行信息（ad . therapy . 5/2025）

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202570012

引用次数: 0

Antibiotic–Polycationic Peptide Conjugation as an Effective Strategy to Overcome Daptomycin Resistance (Adv. Therap. 5/2025) 抗生素-多阳离子肽偶联作为克服达托霉素耐药的有效策略（ad . therapy . 5/2025）

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202570011

Sari Rasheed, Florian Umstätter, Eric Mühlberg, Barbro Beijer, Tobias Hertlein, Karel D. Klika, Christian Kleist, Julia Werner, Cornelius Domhan, Mara Bingel, Anna Müller, Marvin Rausch, Stefan Zimmermann, Knut Ohlsen, Uwe Haberkorn, Marcus Koch, Markus Bischoff, Tanja Schneider, Rolf Müller, Jennifer Herrmann, Walter Mier, Philipp Uhl

引用次数: 0

Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody-Drug Conjugate 使用CD24抗体-药物偶联物治疗骨肉瘤和肺转移的临床前模型

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202400423

Peng Guo, Yuxuan Li, Jing Huang, Liming Jin, Xing Liu, Dawei He, Marsha A. Moses

{"title":"Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody-Drug Conjugate","authors":"Peng Guo, Yuxuan Li, Jing Huang, Liming Jin, Xing Liu, Dawei He, Marsha A. Moses","doi":"10.1002/adtp.202400423","DOIUrl":"10.1002/adtp.202400423","url":null,"abstract":"Pulmonary metastases present a significant clinical challenge in the treatment of osteosarcoma (OS). The current therapeutic landscape for metastatic OS is limited by the lack of effective targeted therapies. Here, the development and preclinical evaluation of a novel CD24 antibody-drug conjugate (ADC) designed for the targeted ablation of primary OS tumors and pulmonary metastases are reported. An unbiased, quantitative screening of cancer-related cell surface markers on human OS cells identifies CD24 as a novel target for ADC therapy in OS, owing to its disease-specific overexpression and rapid antigen-mediated internalization. Based on these findings, a proof-of-concept ADC, comprising a humanized CD24 antibody conjugated with mertansine (CD24-DM1), was designed and constructed. CD24-DM1 demonstrated potent cytotoxicity against a panel of human OS cell lines while sparing normal human osteoblasts. In an orthotopic OS model, CD24-DM1 induced complete and durable tumor regression. Additionally, CD24-DM1 significantly delayed tumor growth in a lung-metastatic OS model, providing robust in vivo evidence of CD24 as a promising ADC target for OS therapy. In conclusion, CD24-DM1 exhibits a favorable therapeutic index for the treatment of metastatic OS in preclinical models, highlighting its potential as an effective targeted therapeutic option.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 6","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144308849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the Potential of Stimuli-Responsive Double-Network DNA Hydrogels Toward Nanotheranostics 利用刺激反应双网络DNA水凝胶在纳米治疗中的潜力

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-10 DOI: 10.1002/adtp.202500036

Kishika Arora, Shikha Awasthi

{"title":"Harnessing the Potential of Stimuli-Responsive Double-Network DNA Hydrogels Toward Nanotheranostics","authors":"Kishika Arora, Shikha Awasthi","doi":"10.1002/adtp.202500036","DOIUrl":"10.1002/adtp.202500036","url":null,"abstract":"The convergence of hydrogel science and Deoxyribonucleic acid (DNA) nanotechnology has led to the development of an innovative category of materials: double-network (DN) DNA hydrogels. These hydrogels are gaining consequential attention because they show advanced responsiveness toward functional stimuli, thus revealing their remarkable potential in therapeutics. This review comprehensively examines the different strategies for synthesizing double-network (DN) DNA hydrogels, delving into their classification based on their response to biological and nonbiological stimuli. This highlights the innovative methodologies that enable the design of these hybrid hydrogels, which guarantee high-toughness and low-cost materials. This review also reports certain recent studies on these hydrogels, emphasizing the intricate relationship between the structure and performance of DN DNA hydrogels and confirming their tailored mechanical properties achieved through programmable DNA sequences and versatile ligation techniques. This report not only provides an overview of the mechanical properties of DNA hydrogels from a synthetic standpoint for various applications but also discusses methods for regulating these properties. Therefore, this report anticipates that readers will procure an ample portrayal of innovative synthesis techniques, diverse classifications, and promising applications of DN-DNA hydrogels, offering a roadmap for future research and development in this transformative area of materials science.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted Oral Delivery of Exosomal Formulation of Cannabidiol against Lung Cancer 靶向口服大麻二酚外泌体制剂治疗肺癌

IF 2.6 4区医学

Advanced Therapeutics Pub Date : 2025-05-09 DOI: 10.1002/adtp.202400362

Disha Nagesh Moholkar, Raghuram Kandimalla, Jeyaprakash Jeyabalan, Jun Yan, Zhao-Hui Song, Farrukh Aqil, Ramesh C. Gupta

{"title":"Targeted Oral Delivery of Exosomal Formulation of Cannabidiol against Lung Cancer","authors":"Disha Nagesh Moholkar, Raghuram Kandimalla, Jeyaprakash Jeyabalan, Jun Yan, Zhao-Hui Song, Farrukh Aqil, Ramesh C. Gupta","doi":"10.1002/adtp.202400362","DOIUrl":"10.1002/adtp.202400362","url":null,"abstract":"Despite advances in the treatment of lung cancer, the survival rate remains low due to lack of specificity and selectivity. The use of appropriate nano-drug delivery vehicle can overcome these issues. Cannabidiol (CBD) has the potential to be used as a novel therapeutic agent for treating cancer. The study utilizes colostrum-derived exosomes as nano-carriers for the delivery of CBD to overcome its low oral bioavailability. Exosomes are isolated from colostrum powder by sequential ultracentrifugation. Following CBD loading the formulations (ExoCBD and FA-ExoCBD) are characterized for their physical parameters (size, charge, and zeta potential). Cell culture assays (MTT, colony forming) are performed to analyze the anti-cancer activity of CBD and ExoCBD against drug-sensitive and resistant lung cancer cells and followed by orthotopic lung tumor xenograft mouse-model. FA-functionalized exosomal formulation of CBD provides a drug load of 20–24%. CBD and its exosomal formulations show antiproliferative and anti-inflammatory activities against both lung cancer cells and reduce the colony forming ability. Mechanistically, CBD decreased the expression of CB2, cell cycle markers, NF-κB, and IκBα, while increasing GPR3 levels in both drug-sensitive and drug-resistant lung cancer cells, as well as MDR-1 in drug-resistant cells. Orally administered FA-ExoCBD shows superior tumor growth inhibition as compared to free CBD (80% vs 60%) at one-half the dose of 7.5 mg kg−1 versus 15 mg kg−1. FA-ExoCBD can be developed as a potential targeted oral drug in the quest of lung cancer management.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 7","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0